Pine Bark study

About the Pine Bark study

Obesity and diabetes are epidemic in New Zealand (and in other Western countries), and many individuals now have problems controlling their blood glucose levels within normal levels. More alarmingly, approximately 40% of individuals with normal glucose tolerance (NGT) may still eventually develop type 2 diabetes. This study aims to examine two doses (50 and 400 mg) of the New Zealand pine bark extract (EnzogenolTM) and its impact on blood glucose and insulin levels when it is consumed together with a sucrose solution.

Inclusion criteria

To apply to take part, you must be:

• healthy (any gender)
• aged 18 to 60 years old
• able to communicate well in English

Participants should have:

• Body Mass Index (BMI) of 18.5-29.9kg/m2 (BMI is calculated using formula body weight (kg)/ height (m) x height (m))
• glycated haemoglobin A1c (HbA1c) <39 mmol/mol (According to American Diabetes Association (ADA) guidelines)
• fasting blood glucose (FBG) <5.6 mmol/L (ADA guidelines)

If you do not know your BMI, glycated haemoglobin or fasting blood glucose, we can help you measure these when we invite you over for screening.

Register your interest

If you’re interested in taking part, fill in the Pine Bark study registration of interest form.